Seattle Genetics: Why a selloff following good news

Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody drug Enfortumab Vedotin in locally advanced or metastatic urothelial cancer, the stock experienced a selloff.
Prohost Observations  
We do not believe that there is anything wrong with the positive results coming out of  EV-201 trial investigating Enfortumab Vedotinfor locally advanced or metastatic urothelial cancer who have received previous treatment with both platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor. Enfortumab Vedotin demonstrated . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.